Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO
Rapid Data Pulses From ASCO 2026: Emerging Data on Oral Targeted Strategies in Breast Cancer
Erica L. Mayer, MD, MPH
Target Locked in gMG: Why T2T Matters
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
Turning Flares Into Function: Flag Uncontrolled Disease
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
The IgG Clock: Redose Using IgG Kinetics
When to Begin FcRn: Initiation Criteria, Key Evidence
Shared Goals, Shared Gains: Align With Patient Preferences
Escalate With Intention: Stepwise, Target-Anchored Moves
FcRn: Same Class, Different Paths—Spot Agent Differentiators
ENDOVOICE Live: Endometriosis—A Chronic Burden of Reproductive Years
Linda Bradley, MD
Obianuju Sandra Madueke-Laveaux, MD, MPH
Lauren R. Kornegay
Diagnosing and Treating IBS: It Begins With One Simple Question
Brooks D. Cash, MD, AGAF, FACG, FACP, FASGE
Kimberly D. Orleck, PA-C
The Alloimmune Disorders of Pregnancy
Karin J. Blakemore, MD
Emilie L. Vander Haar
Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT): Overcoming Diagnostic and Therapeutic Challenges
Cut to the Chase: Why Not Treat Endometriosis With GnRH Antagonists First?
Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
Sawsan As-Sanie, MD
James A. Simon, MD, CCD, NCMP, IF, FACOG
Pre- and Postoperative Use of GnRH Antagonists
Lee P. Shulman, MD, FACMG, FACOG
Loading...
We're glad to see you're enjoying Omnia Education… but how about a more personalized experience?
Press cancel to remain on Omnia Education. Press the link below or the continue button to keep going.